Overview

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
Phase:
Phase 2
Details
Lead Sponsor:
Eliem Therapeutics (UK) Ltd.